Intestinal Microbiota and Treatment of GD

Microbiota Clinical Trial

Official title: The Effect of Intestinal Microbiota on Treatment Sensitivity and Prognosis of Methimazole for GD

Status Recruiting

Clinical Trial Summary

Graves' disease is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers. Many studies have indicated that alterations in the gut microbiota are important environmental factors in the development of inflammatory and autoimmune diseases. Investigators systematically performed a comparative analysis of the gut microbiota in GD patients and healthy controls and analyse the relationship between intestinal microbiota and GD drug therapy.

Clinical Trial Description

Graves' disease is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers. Many studies have indicated that alterations in the gut microbiota are important environmental factors in the development of inflammatory and autoimmune diseases. Investigators systematically performed a comparative analysis of the gut microbiota in GD patients and healthy controls before and found that gut microbiota changed between GD patients and healthy controls.But there are few articles on the relationship between intestinal microbiota and drug treatment of GD, so Investigators explored the relationship between intestinal microflora and methimazole treatment for GD. ;

Related Conditions & MeSH terms

• Microbiota

• NCT number: NCT03433352
• Study type: Observational
• Source: First Affiliated Hospital of Harbin Medical University
• Contact: Yunwei Wei
• Phone: +86-0451-85553099
• Email: hydwyw11@hotmail.com
• Status: Recruiting
• Phase: N/A
• Start date: December 23, 2017
• Completion date: December 20, 2019